FDA Unveils Rules for Custom Orthopedic Implants Tailored to Patients
Published Date: 5/7/2026
Notice
Summary
The FDA just released new guidance to help companies make and submit patient-matched guides for orthopedic implants. This means clearer rules and smoother reviews for devices tailored to each patient’s body. Manufacturers should start following these tips now to speed up approvals and avoid costly delays.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Clear submission tips to speed reviews
The FDA released final guidance titled "Patient-Matched Guides for Orthopedic Implants" on May 7, 2026 that gives companies recommendations on what information to include in regulatory submissions and on design practices. If manufacturers follow these recommendations, the FDA says it may increase efficiency and consistency in review, which can help speed approvals and reduce review-related delays.
Clarified triggers for new 510(k) submissions
The guidance clarifies certain design modifications that the FDA would consider likely to require submission of a new 510(k). If a manufacturer makes those kinds of modifications, they may need to submit a new 510(k), which can add regulatory steps and costs.
No new paperwork collections required
The guidance states it contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved FDA information collections (for example, 21 CFR parts and OMB control numbers listed in the notice). This means the guidance does not add new paperwork requirements for manufacturers.
Guidance is non-binding; alternatives allowed
The FDA says the guidance represents its current thinking and is not binding on FDA or the public; manufacturers may use alternative approaches if those approaches satisfy applicable statutes and regulations. This preserves flexibility for companies in how they meet regulatory requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2026-09022 — Colorado River Basin Salinity Control Advisory Council Notice of Public Meeting
The Colorado River Basin Salinity Control Advisory Council is holding a public meeting on May 13-14, 2026, to share updates and plan future efforts to keep the river’s water clean and less salty. This affects farmers, cities, and wildlife relying on the river, with agencies working together to protect water quality. The meeting is both in-person in Las Vegas and online, making it easy for everyone to join and stay informed.
Next: 2026-09025 — Accreditation and Approval of SGS North America, Inc. (Texas City, TX) as a Commercial Gauger
SGS North America, Inc. in Texas City just got the green light to measure petroleum products for U.S. Customs starting May 7, 2025, and this approval lasts for three years. This means businesses dealing with petroleum can trust SGS for accurate gauging without delays or extra costs. The next check-up for SGS will happen in May 2028, keeping everything on track and official.